Mode
Text Size
Log in / Sign up

Isolated gastric Kaposi sarcoma occurs following allogeneic hematopoietic stem cell transplantation in rare casesRare Gastric Kaposi Sarcoma Found After Stem Cell Transplant

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Kaposi sarcoma in the differential diagnosis of gastrointestinal symptoms following allogeneic hematopoietic stem cell transplantation.

This case report and literature review examines the occurrence of Kaposi sarcoma (KS) following allogeneic hematopoietic stem cell transplantation (HSCT). The authors identified 20 cases in the literature to characterize the presentation, timing, and management of the disease in this specific patient population.

Findings indicate that most cases of KS occurred within the first year after transplantation while patients were on immunosuppression. While cutaneous involvement was the predominant presentation, isolated visceral disease was noted as exceptionally uncommon. However, the presence of visceral involvement was associated with poorer outcomes. The most frequent treatment strategy reported was the reduction or discontinuation of immunosuppression.

A primary limitation noted is the small sample size of 20 cases in the literature review. The report highlights the importance of including KS in the differential diagnosis for gastrointestinal symptoms following HSCT. Clinicians are encouraged to perform early endoscopic biopsies with HHV-8 immunohistochemical evaluation when clinical suspicion is high.

How this fits prior evidence

This report addresses a gap in the clinical recognition of visceral manifestations of Kaposi sarcoma following hematopoietic stem cell transplantation. While prior coverage notes the use of pomalidomide for Kaposi sarcoma, this evidence specifically highlights the rare occurrence of isolated gastric involvement and the associated poorer outcomes in post-transplant patients.

Doctors identified a rare case of Kaposi sarcoma involving only the stomach in a patient who underwent an allogeneic hematopoietic stem cell transplantation. While Kaposi sarcoma is often seen on the skin, finding it only in the internal organs is very uncommon. This specific case was unique because no other reported cases of isolated stomach involvement were found in the existing medical literature.

A review of 20 other cases showed that most patients develop skin symptoms within the first year of transplant while on immune-suppressing drugs. When the disease affects internal organs, such as the stomach, the medical outlook is often poorer. This finding suggests that doctors should look closely at the stomach when patients show digestive issues after a transplant.

Because this evidence comes from a single case and a small review of 20 cases, it is not enough to change standard medical practices. However, it highlights the importance of using endoscopic biopsies to check for specific markers. Patients with symptoms after a transplant should discuss their specific risks and symptoms with their medical team.

What this means for you:
Isolated stomach Kaposi sarcoma is rare after stem cell transplants and may require early endoscopic testing.

Common questions

Is it common for Kaposi sarcoma to affect the stomach?

No, it is not common. The study found that skin involvement is the most common way this condition appears. Isolated internal organ involvement, like the stomach, is described as exceptionally uncommon in the reviewed cases.

When does Kaposi sarcoma usually appear after a transplant?

Most cases of Kaposi sarcoma were found within the first year after a transplant while the patient was taking immunosuppression medications. This timing is important for doctors to monitor patients closely during the first year.

What is the typical treatment for this condition?

The most frequent treatment option reported for Kaposi sarcoma in these cases was the reduction or discontinuation of immunosuppression medications. You should speak with your doctor about specific treatment plans.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundKaposi sarcoma (KS) is a rare complication after hematopoietic stem cell transplantation (HSCT).Case presentationWe report a 20-year-old male with severe aplastic anemia who underwent HLA-matched sibling allogeneic HSCT. Three months later, he developed abdominal pain, nausea, and diarrhea suspected to represent gastrointestinal graft-versus-host disease. Endoscopic evaluation revealed multiple ulcerated gastric nodules, and histopathologic examination demonstrated spindle-cell proliferation with positive HHV-8 and CD34 immunostaining, confirming KS. Staging with computed tomography of the chest, abdomen, and pelvis showed no additional visceral involvement, and examination of the skin and mucous membranes showed no evidence of cutaneous or mucosal disease. Immunosuppression was gradually tapered. However, the patient developed rapidly progressive respiratory failure with positive blood HHV-8 polymerase chain reaction. HHV-8 pneumonitis was suspected but could not be confirmed, and the patient died despite supportive management.ResultsA literature review identified 20 reported cases of KS following HSCT. Most cases occurred within the first year after transplantation while on immunosuppression. Cutaneous involvement was the predominant presentation, whereas isolated visceral disease was exceptionally uncommon. Reduction or discontinuation of immunosuppression was the most frequent treatment option, while visceral involvement was associated with poorer outcomes.ConclusionTo our knowledge, no previously published case of isolated gastric KS following allogeneic HSCT was identified in our literature search. It highlights the importance of considering KS in the differential diagnosis of gastrointestinal symptoms after HSCT and supports early endoscopic biopsy with HHV-8 immunohistochemical evaluation to facilitate timely diagnosis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.